ISB News

ISB in Antarctica: Research Cruise Life

By Allison Lee

I just want to illustrate the work life out here. I have worked 20 straight days in a row. No weekends. No evenings off. Few breaks. Each day varies in time schedule but it usually consists of waking up at 7 a.m., taking at least two shots of espresso before working until lunch at 11:30 a.m. -12:30 p.m., working until dinner 5:30 p.m.-6:30 p.m. and working until 11 p.m., sometimes even until 2 a.m. It’s a good day when you can throw an hour in for an INSANITY work-out or a sauna break and get more than 7 hours of sleep. “Downtime” consists of uploading my Facebook photos, writing up blog drafts, organizing data, and reading textbooks on the Southern Ocean (all still work related). We all are starting to feel the strong desire for a weekend. And a beer. Just. One. Beer. On that note: Week three and we are out of fresh vegetables and fruits. It’s time for the canned goods, meat, carbs and cheese. I’m not complaining at all! I’m just sharing the reality of research life at sea. Only 38 more days to go! MISS YOU ALL XOXO

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.